Jo H, Park P, Yu Y, Choi Y, Yu S, Kim D
Hepatobiliary Surg Nutr. 2024; 13(5):814-823.
PMID: 39507744
PMC: 11534781.
DOI: 10.21037/hbsn-23-578.
Hao K, Paik A, Han L, Makary M
World J Radiol. 2024; 16(10):512-527.
PMID: 39494134
PMC: 11525828.
DOI: 10.4329/wjr.v16.i10.512.
Tang X, Chen J, Peng W, Yang Z, Hu L, Ye Z
Immunotargets Ther. 2024; 13:559-569.
PMID: 39478940
PMC: 11524013.
DOI: 10.2147/ITT.S478685.
Galasso L, Cerrito L, Termite F, Mignini I, Esposto G, Borriello R
Cancers (Basel). 2024; 16(19).
PMID: 39409869
PMC: 11482560.
DOI: 10.3390/cancers16193247.
Tan H, Liu S, Zheng J, Liu H, Liu Y, Dai G
Abdom Radiol (NY). 2024; 50(3):1320-1329.
PMID: 39392475
DOI: 10.1007/s00261-024-04620-1.
ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization.
Gelardi F, Rodari M, Pini C, Zanca R, Artesani A, Tosi G
Front Nucl Med. 2024; 2:934446.
PMID: 39354974
PMC: 11440852.
DOI: 10.3389/fnume.2022.934446.
Research Progress in Predicting Hepatocellular Carcinoma with Portal Vein Tumour Thrombus in the Era of Artificial Intelligence.
Li Y, Fan N, He X, Zhu J, Zhang J, Lu L
J Hepatocell Carcinoma. 2024; 11:1429-1438.
PMID: 39050809
PMC: 11268770.
DOI: 10.2147/JHC.S474922.
Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.
Mulyadi R, Hasan I, Sidipratomo P, Putri P
J Egypt Natl Canc Inst. 2024; 36(1):18.
PMID: 38797810
DOI: 10.1186/s43046-024-00224-4.
Neoadjuvant targeted immunotherapy followed by surgical resection versus upfront surgery for hepatocellular carcinoma with macrovascular invasion: A multicenter study.
Wu X, Wang Y, Wang S, Chen Y, Han J, Wang C
J Cancer. 2024; 15(10):3024-3033.
PMID: 38706890
PMC: 11064256.
DOI: 10.7150/jca.94539.
Co-relation of Portal Vein Tumour Thrombus Response With Survival Function Following Robotic Radiosurgery in Vascular Invasive Hepatocellular Carcinoma.
Dutta D, Yarlagadda S, Kalavagunta S, Nair H, Sasidharan A, Nimmya S
J Clin Exp Hepatol. 2024; 14(5):101404.
PMID: 38680618
PMC: 11053332.
DOI: 10.1016/j.jceh.2024.101404.
Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.
Yang L, Wang H, Li S, Gan G, Deng W, Chang Y
World J Gastroenterol. 2024; 30(11):1533-1544.
PMID: 38617449
PMC: 11008421.
DOI: 10.3748/wjg.v30.i11.1533.
Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis.
Lim M, Kim J, Rhu J, Choi G, Joh J
J Liver Cancer. 2024; 24(1):102-112.
PMID: 38351676
PMC: 10990670.
DOI: 10.17998/jlc.2024.01.31.
Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis.
Vogel A, Finn R, Blanchet Zumofen M, Heuser C, Alvarez J, Leibfried M
Liver Cancer. 2023; 12(6):510-520.
PMID: 38058419
PMC: 10697759.
DOI: 10.1159/000533166.
Survival of Trial-Like and Non-Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP).
Ramaswamy A, Kulkarni A, John G, Rauthan A, Patil S, Duseja A
JCO Glob Oncol. 2023; 9:e2300215.
PMID: 38033275
PMC: 10703119.
DOI: 10.1200/GO.23.00215.
Metastatic papillary renal cell carcinoma with portal vein tumor thrombosis confirmed on blind liver biopsy.
Kim H, Roh T, Lee J, Kim M, Kim B
J Liver Cancer. 2023; 24(1):113-117.
PMID: 38017367
PMC: 10990669.
DOI: 10.17998/jlc.2023.11.05.
Reappraisal of Portal Vein Tumor Thrombosis as a Prognostic Factor for Patients with Hepatocellular Carcinoma.
Chang Y, Yu S, Kim H, Lee Y, Cho E, Lee J
Gut Liver. 2023; 18(1):156-164.
PMID: 38013475
PMC: 10791491.
DOI: 10.5009/gnl230057.
Transplant Oncology: An Emerging Discipline of Cancer Treatment.
Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Victor D, Kodali S
Cancers (Basel). 2023; 15(22).
PMID: 38001597
PMC: 10670243.
DOI: 10.3390/cancers15225337.
The Role of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Neoplastic Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma.
Cerrito L, Ainora M, Di Francesco S, Galasso L, Gasbarrini A, Zocco M
Tomography. 2023; 9(5):1976-1986.
PMID: 37888746
PMC: 10610687.
DOI: 10.3390/tomography9050154.
A novel prognostic scoring system to predict portal vein tumor thrombosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li M, Dang Z, Ma S, Wang Y, Xu X, Li B
Am J Transl Res. 2023; 15(7):4600-4609.
PMID: 37560212
PMC: 10408526.
Portal vein thrombosis in patients with hepatocellular carcinoma and early cirrhosis-prevalence and risk factors.
Siddiqui M, Fareed G, Khan M, Riaz A, Hamid S
Ecancermedicalscience. 2023; 17:1581.
PMID: 37533945
PMC: 10393302.
DOI: 10.3332/ecancer.2023.1581.